

2nd August 2023

**BSE Limited**

1<sup>st</sup> Floor, New Trading Ring,  
Rotunda Bldg, P.J. Towers,  
Dalal Street,  
Mumbai- 400 001.

**National Stock Exchange of India Limited**

Exchange Plaza, 5<sup>th</sup> Floor,  
Plot No. C/1, G. Block,  
Bandra Kurla Complex, Bandra (East),  
Mumbai - 400 051.

Script Code: 500259

Script Code: LYKALABS

Dear Sir/Madam,

**Sub.: Outcome of Board Meeting held on 2nd August 2023**

In Compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015; this is to inform you that the Board of Directors at its Meeting held today i.e. 2nd August 2023 *inter alia* considered and approved Unaudited Standalone and Consolidated Financial Results for the quarter ended 30th June 2023 together with the Limited Review Reports thereon.

The said Financial Results along with Limited Review Report are attached herewith.

The meeting of the Board of Directors commenced at 01:00 p.m. and concluded at 01:50 p.m.

We request you to take the above information on your record.

Thanking You,

Yours faithfully,  
For Lyka Labs Limited

**Kishore P. Shah**  
Company Secretary & Compliance Officer  
Encl.: A/a.

## Statement of Standalone Unaudited Financial Results for the Quarter Ended 30th June, 2023

(₹ in lakh)

Particulars	Quarter Ended			Year Ended
	30th June, 2023	31st March, 2023	30th Jun, 2022	31st March, 2023
	(Unaudited)	(Audited)	(Unaudited)	(Audited)
<b>I. Revenue</b>				
Revenue from Operations	2,123.70	1,945.51	2,187.84	8,059.26
Other Income	42.83	61.48	68.39	345.16
<b>II. Total Income</b>	<b>2,166.53</b>	<b>2,006.99</b>	<b>2,256.23</b>	<b>8,404.42</b>
<b>III. Expenses</b>				
(a) Cost of Materials Consumed	609.42	535.22	683.84	2,307.57
(b) Purchase of Stock in trade	360.19	144.62	194.06	719.42
(c) Change in inventories of finished goods, work-in-progress and stock-in-trade,	(112.31)	(24.37)	(65.06)	(120.71)
(d) Employee benefits expense	566.57	497.10	370.84	1,748.30
(e) Finance Costs	133.33	281.31	280.06	1,157.00
(f) Depreciation and amortisation expense	333.54	332.25	341.36	1,351.64
(g) Other expenses	444.07	519.91	412.16	1,844.63
<b>Total Expenses</b>	<b>2,334.81</b>	<b>2,286.04</b>	<b>2,217.26</b>	<b>9,007.85</b>
<b>IV. Profit / (Loss) before Exceptional Items and Taxes (II - III)</b>	<b>(168.28)</b>	<b>(279.05)</b>	<b>38.97</b>	<b>(603.43)</b>
<b>V. Exceptional Items (Net)</b>	-	13.93	0.08	717.41
<b>VI. Profit / (Loss) before Tax</b>	<b>(168.28)</b>	<b>(292.98)</b>	<b>38.89</b>	<b>(1,320.84)</b>
<b>VII. Tax Expenses</b>				
Current Tax	23.50	(34.75)		20.70
Deferred Tax	(19.79)	42.30	6.06	(12.88)
<b>VIII. Net Profit / (Loss) after Tax</b>	<b>(171.99)</b>	<b>(300.53)</b>	<b>32.83</b>	<b>(1,328.66)</b>
<b>IX. Other Comprehensive Income (Net of Tax) - Net Credit / (Charge)</b>	<b>(1.57)</b>	<b>3.24</b>	<b>(3.18)</b>	<b>(6.28)</b>
<b>X. Total Comprehensive Income / (Loss)</b>	<b>(173.56)</b>	<b>(297.29)</b>	<b>29.65</b>	<b>(1,334.94)</b>
Paid up Equity Share Capital (Face value ₹ 10/- each)	3,309.00	3,069.00	2,869.00	3,069.00
Other Equity				4,573.63
<b>XI. Basic and diluted earnings per share</b>	<b>(0.54)</b>	<b>(1.05)</b>	<b>0.11</b>	<b>(4.65)</b>

### Notes:

- The above unaudited standalone financial results were considered by the Audit Committee at its meeting held today which was approved and taken on record at the meeting of the Board of Directors held on 2nd August, 2023.
- During the quarter ended June 2023, out of 50,00,000 warrants convertible into equity shares; 24,00,000 warrants were converted into equity shares, on receipt of balance amount of 75% of the issue price of Rs.139.50 (including premium) per warrant.
- The Company operates in one reportable business segment i.e. "Pharmaceuticals".
- The figures for the previous year have been regrouped / rearranged wherever considered necessary.
- The Statutory Auditors have expressed an unqualified opinion on the unaudited standalone financials results for the quarter ended 30th June, 2023.



Mumbai; 2nd August, 2023

For Lyka Labs Limited

Kunal N. Gandhi  
 Managing Director & CEO  
 DIN 01516156



# D. KOTHARY & CO.


## Chartered Accountants

Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to  
The Board of Directors  
Lyka Labs Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results of Lyka Labs Limited (the "Company") for the quarter ended June 30, 2023 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, read with the Circular is the responsibility of the Company's management and has been approved by the Board of Directors of the Company. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. A review is substantially less in scope than an audit conducted in accordance with Standards of Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of the Listing Regulations, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For D. Kothary & Co.  
Chartered Accountants  
Firm Registration No. 105335W

  
Mehul N. Patel  
Partner  
Membership No. 132650

UDIN: 23132650 B6PYCK5362

Place: Mumbai  
Date: 2nd August, 2023



## Statement of Consolidated Unaudited Financial Results for the Quarter Ended 30th June, 2023

(₹ in lakh)

Particulars	Quarter Ended			Year ended
	30th June, 2023 (Unaudited)	31st March, 2023 (Audited)	30th June, 2022 (Unaudited)	31st March, 2023 (Audited)
<b>I. Revenue</b>				
Revenue from Operations	2,287.70	2,223.86	2,749.20	9,307.28
Other Income	37.56	42.88	71.78	340.10
<b>II. Total Income</b>	<b>2,325.26</b>	<b>2,266.74</b>	<b>2,820.98</b>	<b>9,647.38</b>
<b>III. Expenses</b>				
(a) Cost of Materials Consumed	609.42	535.22	683.84	2,307.57
(b) Purchase of Stock in trade	453.89	283.15	644.78	1,568.69
(c) Change in inventories of finished goods, work-in-progress and stock-in-trade,	-112.34	(24.37)	(65.25)	(120.81)
(d) Employee benefits expense	593.52	522.54	401.24	1,860.51
(e) Finance Costs	135.14	284.74	290.71	1,187.03
(f) Depreciation and amortisation expense	346.69	346.57	358.62	1,414.73
(g) Other expenses	478.79	577.77	454.39	2,007.33
<b>Total Expenses</b>	<b>2,505.11</b>	<b>2,525.62</b>	<b>2,768.33</b>	<b>10,225.05</b>
<b>IV. Profit / (Loss) before Exceptional Items and Taxes (II - III)</b>	<b>(179.85)</b>	<b>(258.88)</b>	<b>52.65</b>	<b>(577.67)</b>
<b>V. Exceptional Items (Net)</b>		41.14	(23.43)	739.44
<b>VI. Profit / (Loss) before Tax</b>	<b>(179.85)</b>	<b>(300.02)</b>	<b>76.08</b>	<b>(1,317.11)</b>
<b>VII. Non Controlling Interest</b>	(8.42)	1.16	11.20	5.94
<b>VIII. Profit / (Loss) before Tax</b>	<b>(171.43)</b>	<b>(301.18)</b>	<b>64.88</b>	<b>(1,323.05)</b>
<b>IX. Tax Expenses</b>				
Current Tax / Earlier Year Tax	34.31	(35.00)		20.45
Deferred Tax	-21.07	34.56	5.35	(22.32)
<b>X. Net Profit / (Loss) after Tax</b>	<b>(184.67)</b>	<b>(300.74)</b>	<b>59.53</b>	<b>(1,321.18)</b>
<b>XI. Other Comprehensive Income (Net of Tax) - Net Credit / (Charge)</b>	-1.57	2.18	(3.18)	(3.63)
<b>XII. Total Comprehensive Income / (Loss)</b>	<b>(186.24)</b>	<b>(298.56)</b>	<b>56.35</b>	<b>(1,324.81)</b>
<b>XIII. Paid up Equity Share Capital (Face value Rs.10/- each) Other Equity</b>	3,309.00	3,069.00	2,869.00	3,069.00
<b>XIV. Basic and diluted earnings per share</b>	(0.57)	(1.05)	0.20	(4.63)

Notes:

- The above unaudited consolidated financial results were considered by the Audit Committee at its meeting held today which has been approved and taken on record at the meeting of the Board of Directors held 2nd August, 2023.
- During the quarter ended June 2023, out of 50,00,000 warrants convertible into equity shares; 24,00,000 warrants were converted into equity shares, on receipt of balance amount of 75% of the issue price of Rs.139.50 (including premium) per warrant.  
Further, such 24,00,000 equity shares were issued and allotted to Ipca Laboratories Limited. Hence, our Equity Capital and Securities premium shall stand increased proportionately.
- The Group operates in one reportable business segment i.e. "Pharmaceuticals".
- The figures for the previous year have been regrouped / rearranged wherever considered necessary.
- The Statutory Auditors have expressed an unqualified opinion on the unaudited consolidated financials results for the quarter ended 30th June, 2023.



Mumbai, 2nd August, 2023

Regd. Office : 4801 / B & 4802 / A, G.I.D.C. Industrial Estate, Ankleshwar - 393 002.

• Phone : 02646 221422 / 220549 • Fax : 02640-250692

CIN L24230GJ1976PLC008738

For Lyka Labs Limited

  
**Kunal N. Gandhi**  
 Managing Director & CEO  
 DIN 01516156



# D. KOTHARY & CO.

## Chartered Accountants

Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to  
The Board of Directors  
Lyka Labs Limited

1. We have reviewed the accompanying Statement of unaudited Consolidated Financial Results of Lyka Labs Limited (the "Parent"), which includes its subsidiary (the Parent and its subsidiary together referred to as "the Group"), for the quarter ended June 30, 2023 (the "Statement") attached herewith, being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India read with the Circular. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, to the extent applicable.

4. The Statement includes the results of following entities:  
**Subsidiaries**
  - i) Lyka BDR International Limited
  - ii) Lyka Exports Limited
5. The accompanying statement includes the interim financial results and other financial information in respect of 2 subsidiaries, whose interim financial results/information reflects total revenues of Rs. 180.71 lakhs, total net Profit/ (Loss) after tax of Rs. (21.12) lakhs for the quarter ended June 30, 2023, which have been reviewed by us.





## **D. KOTHARY & CO.** **Chartered Accountants**

6. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standard specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For D. Kothary & Co.**  
Chartered Accountants  
Firm Registration No. 105335W

**Mehul N. Patel**  
Partner  
Membership No. 132650



UDIN: 23132650BGPYCL6994 .

Place: Mumbai  
Date: 2nd August, 2023